Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
Blood
; 119(26): 6379-81, 2012 Jun 28.
Article
de En
| MEDLINE
| ID: mdl-22611160
ABSTRACT
Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the efficacy and safety of subsequent reduced-intensity allo-HCT. Seventeen patients had previous autologous transplant; 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from unrelated or mismatched donors. The 1-year overall survival was 100%, progression-free survival was 92.3%, and nonrelapse mortality was 0% (median follow-up, 14 months). The incidence of acute GVHD was 27.8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Maladie de Hodgkin
/
Immunoconjugués
/
Transplantation de cellules souches hématopoïétiques
Type d'étude:
Evaluation_studies
/
Observational_studies
/
Risk_factors_studies
Limites:
Adult
/
Humans
/
Middle aged
Langue:
En
Journal:
Blood
Année:
2012
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique